10/17/2023
https://congress.gov...
"Even with charging those lower prices, does Teva turn a profit in Europe?"
"And while Teva was forced to put pressure, was forced to lower the price in Europe, in that same two-year period, the company raised the price on U.S. multiple sclerosis patients by 60 percent."
"So, Mr. Schultz, why is the price of Copaxone so much higher for people with multiple sclerosis in the United States than those in other countries?"
"But that is quite all right, thank you. Thankfully, we do know, and the answer is that it was."